{
  "docId": "019de075-7c2e-7510-9012-23bac78506e5",
  "docSlug": "6afb08ad9ecba2144545352067526476",
  "documentTitle": "Bluejay | Investor Presentation Deck | 20 slides",
  "authorId": "bluejay",
  "authorName": "Bluejay Diagnostics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 20,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 18,
  "notes": "The table highlights NPV as the key differentiator. The ROC chart visually confirms IL-6's superior AUC.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7c2e-7510-9012-23bac78506e5/11",
  "deckHref": "/decks/019de075-7c2e-7510-9012-23bac78506e5",
  "deckJsonHref": "/decks/019de075-7c2e-7510-9012-23bac78506e5.json",
  "deckAnchorHref": "/decks/019de075-7c2e-7510-9012-23bac78506e5#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.3,
        "x": 0.67,
        "y": 0.2
      },
      "kind": "chart",
      "text": "ROC Curves of Biomarker Prediction of IMV",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "307b29a4-157f-4505-9fc4-06c2f74793d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.73
      },
      "kind": "paragraph",
      "text": "Bluejay clinical study assessed ability of Symphony IL-6 to predict risk for invasive mechanical ventilation (IMV) in COVID-19 patients at time of hospital admission. Favorable clinical performance demonstrated 89% sensitivity, 64% specificity and 98% NPV.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30cfb77c-7d38-4805-b10d-6879d8c7879b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.13,
        "y": 0.093
      },
      "kind": "source-note",
      "text": "Source: 1. Bluejay Diagnostics market research. 2. NPV = Negative Predictive Value. 3. Bluejay/Industry information, pending the location of the testing lab. 4. from FDA Emergency Use Authorization company filings",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56fd4f29-001b-4c9c-9b25-12b89ac6938d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.6,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "table",
      "text": "Metric comparison table for IL-6, CRP, and Lactate across AUC, Youden Index, Cutoff, Sensitivity, Specificity, and NPV.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2afc893b-63c9-49fe-8798-3ee9204d8e38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "title",
      "text": "IL-6 negative predictive value (NPV) superior to other standard biomarkers",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bba1b51-5bed-4d7c-b911-2a5e4fa58320",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Symphony™ IL-6 Potential Clinical Advantages v. Current Tests Used for Sepsis Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94d8321d-8f4a-4ae2-9534-f557bfdd395b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "e1439048-d673-45f6-a7bf-2761e6c59079",
      "evidence": "Direct comparison of clinical metrics between Symphony IL-6 and standard biomarkers.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 20,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "c2e62651-f3f1-4333-88f5-3a258ba00fce",
      "evidence": "The deck implicitly discusses the cost of inaction by emphasizing the life-threatening nature of sepsis and the benefits of rapid diagnosis.",
      "position": 0,
      "objective": "Highlight the cost of not acting quickly in sepsis diagnosis and treatment.",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}